Related Experiment Videos
Metabolic screening
1Boston University School of Medicine, Massachusetts, USA.
Insights
Universal metabolic screening aids early infant diagnosis of treatable disorders. However, pilot studies are crucial to assess screening accuracy and the psychological effects of presymptomatic diagnoses for conditions lacking effective treatments.
Area of Science:
- Medical Genetics
- Pediatric Medicine
- Public Health
Background:
- Mandated, universal metabolic screening effectively identifies infants with metabolic disorders.
- Early diagnosis, especially for treatable conditions, can improve infant outcomes through timely intervention.
- Concerns exist regarding the psychological impact of presymptomatic diagnoses for severe or untreatable diseases.
Purpose of the Study:
- To evaluate the effectiveness of universal metabolic screening in early infant diagnosis.
- To address concerns about the psychological impact of presymptomatic diagnosis.
- To emphasize the need for pilot studies before widespread implementation.
Main Methods:
- Review of existing data on universal metabolic screening programs.
- Analysis of potential benefits versus psychological risks of early diagnosis.
- Emphasis on the necessity of pilot studies for evaluating screening accuracy and outcomes.
Main Results:
- Metabolic screening is effective for early identification of treatable infant metabolic disorders.
- Presymptomatic diagnosis raises psychological concerns, particularly for fatal or untreatable conditions.
- Pilot studies are essential to determine screening sensitivity, specificity, and impact on infant outcomes.
Conclusions:
- Universal metabolic screening offers benefits for early detection of treatable infant disorders.
- Careful evaluation through pilot studies is necessary to balance benefits against potential psychological harm.
- Further research is needed to optimize screening protocols and address the implications of presymptomatic diagnoses.
Abstract:
Mandated, universal metabolic screening has been an effective tool for the early identification of infants with metabolic disorders, particularly those amenable to improved outcome with dietary management or medication. Although the availability of diagnosis long before symptoms occur may be useful to preclude expensive diagnostic evaluation when the subtle early symptoms begin and may allow for genetic counseling and testing in affected families, many concerns have been raised regarding the psychologic impact of presymptomatic diagnosis of diseases that are either fatal or for which no effective treatment is available. Before mass screening is initiated, careful pilot studies need to be done to evaluate sensitivity and specificity as well as the impact of early identification on infant outcome.